Molecular Docking Approach on Thiazolidinedione Analogs as HIV-1-RT Inhibitors

Authors

  • Shikha Sharma
  • Arun Kumar Gupta

Abstract

Potentially life threatening condition due to chronic syndrome caused by human immunodeficiency virus (HIV) is known as Acquired immunodeficiency syndrome(AIDS).Virus weakens the immune system of human being and body’s ability to fight against the organism, thereby causing the disease. When a person becomes infected with HIV, the virus attacks and weakens the immune system. In the given study, molecular docking study was performed on 30polysubstitutedThiazolidinedione (TZD) analogs as HIV-1 reverse transcriptase (HIV-1-RT) inhibitors PDB code: 1RT2 (HIV-1 reverse transcriptase complexed with TNK-651). Molecular docking result revealed that the most active compound was Thio-18 to the active site of protein with amino acid Gly-93, Asn-137 and Gln-161. Further in vitro and in vivo study of TZD analogs can be done for HIV-1-RT inhibitors.

 

Keywords: HIV-1 reverse transcriptase (HIV-1-RT) inhibitors, immunodeficiency, molecular docking, thiazolidinedione (TZD) analogs, TNK-651, PDB 1RT2

 

Cite this Article

Shikha Sharma, Arun Kumar Gupta. Molecular Docking Approach on Thiazolidinedione Analogs as HIV-1-RT Inhibitors. Research & Reviews: A Journal of Bioinformatics. 2020; 7(1): 1–6p.

Downloads

Published

2020-05-11

Issue

Vol. 7 No. 1 (2020)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.